Immunology is undergoing a transformative period, driven by advancements in technology and a deeper understanding of the role that the immune system plays in human health and disease. High-sensitivity proteomic technologies are emerging as indispensable tools in the discovery and screening of clinically relevant biomarkers — in the field of immune related disorders.
NULISA assays have demonstrated the ability to measure previously undetectable levels of critical cytokines and researchers are utilizing these assays to make novel discoveries and associations with clinical outcomes.
Apply for the NULISA Immunology Grant Program for a chance to experience the NULISAseq Immune 340 Panel for your immune-related research.
Immuno-oncology has expanded far beyond checkpoint inhibitors. CAR-T, T-cell engagers, cancer vaccines, antibody-drug conjugates, and combination regimens each activate distinct immune mechanisms: cytotoxic cascades, cytokine release, innate-adaptive crosstalk, and bystander responses. Comprehensive biomarker profiling across checkpoint receptors, the TNF superfamily, and the myeloid suppressor landscape is essential for researching mechanisms associated with treatment response, resistance, and immune-related toxicities such as cytokine release syndrome, neurotoxicity, vascular toxicity, and multi-organ immune toxicity.
Acute inflammatory flares in COPD, asthma, IBD/Crohn’s, and atopic dermatitis are not simply excess inflammation; they reflect dysregulation of distinct immune axes. COPD exacerbations are driven by neutrophilic and macrophage-dominated innate responses amplified by proteolytic tissue destruction. Severe asthma flares involve type 2 alarmin cascades or type 17/neutrophilic mechanisms depending on endotype. IBD flares are mediated by the Th17/IL-23 axis and TNF-driven mucosal damage. Atopic dermatitis is characterized by a type 2 alarmin cascade with chronic barrier dysfunction. Simultaneous measurement of these axes can help researchers characterize pathway activity across disease cohorts and investigate mechanisms associated with therapeutic response.
Autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes are driven by proteins that often circulate at extremely low abundance. Type I interferons in SLE operate at fg/mL levels, below the detection floor of standard multiplex platforms. Shed co-inhibitory receptors, active cleaved caspases, and complement cleavage products all require ultrasensitive measurement to accurately reflect disease activity, predict therapeutic response, and distinguish one autoimmune endotype from another. Capturing the full complement cascade, BAFF/APRIL axis, and low-abundance interferon signatures enables the precision profiling that translational research studies increasingly require.
Infectious disease immunology research demands both breadth and sensitivity. Antiviral responses require discrimination between type I interferons (IFNα/β, systemic antiviral) and type III interferons (IFNλ, mucosal barrier defense), signals that differ in biological relevance fro COVID-19, influenza, and RSV severity stratification but fall below the detection floor of standard platforms. Sepsis research benefits from simultaneous profiling of innate activation and immune suppression to study disease-state transitions and host-response dynamics. For emerging infections, where the pathogen is unknown and the immune response unpredictable, broad, unbiased profiling is an important approach, providing the immune context no targeted assay can match.
Aging and age-related diseases, including cardiovascular, metabolic, neurodegenerative, and cancer, share a common immune thread: inflammaging. Systemic immune dysregulation in aging is diffuse and interconnected, driven by senescence-associated secretory phenotype (SASP) cytokines, myeloid reprogramming, and progressive immune contraction. Neuroinflammation in conditions such as Alzheimer’s, Parkinson’s, ALS, and MS requires integrated immune and neurological profiling from the same sample, tracking microglial activation markers alongside neuroprotective factors. Population health and biobank studies require comprehensive immune readouts at sensitivity levels standard platforms cannot reach, enabling discovery research that targeted panels cannot support.
Comprehensive analysis of health and disease
High sensitivity measurement of validated biomarkers
The NULISA Immunology and Inflammation Panels provide deep, biologically informed coverage of immune cell activation, regulation, communication, and response across health and disease.
Tell us what you want
Prof. Jonathan Schott
Alex Forrest-Hay
Niyati Jhaveri, PhD
Carlos Cruchaga, PhDAlex Forrest-Hay
Steve Williams, MD, PhD
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.
